November 3, 2020 07:13 AM EST
Deals
China
Cell/Gene Tx

Eye­ing com­mer­cial­iza­tion, a Shang­hai-based CAR-T start­up nabs a $186M megaround

Jason Mast

Editor

Three years af­ter its last fi­nanc­ing and with six pro­grams now in the clin­ic, Shang­hai-based CARs­gen ther­a­peu­tics has raised $186 mil­lion to push for­ward a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times